Loading…
← CockpitCompetitor Analysis › PHARM.AS Pharming Group NVOpen in the cockpit ↗

Pharming Group NVPHARM.ASCompetitor analysis, valuation and peers

Netherlands · EUR·Health Care›Pharmaceuticals: Major
Momentum leader 80
Mkt cap
$867M
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$15.3M
20-day average traded
Fwd P/E
34.9×
forward earnings
ROIC−WACC
+6.6 pp
WACC 5.0%
Hurdle
-10 pp
Req g minus delivered
Next earnings
120 days
18 Mar 2027
Close · EUR€1.12
1D-0.4%
1W-5.7%
1M+30.9%
3M+9.9%
6M-5.8%
YTD-21.7%
1Y-21.2%
ATR %3.6%
52w lowhigh38.6% off high

What Pharming does

No business profile yet.

Pharming at a glance

Size Pharming (PHARM.AS) is a Netherlands Health Care company (Pharmaceuticals: Major) with a market value of $867M, the 50th largest of 60 Netherlands companies the cockpit tracks. Shares closed at €1.12 on 18 Nov 2026.

Performance Over six months the shares fell 5.8%, against -26.0% for the median peer and -4.8% for the Netherlands market (cap-weighted) — 3rd highest of 19 in its peer set.

Growth Revenue grew 1.7% over the last twelve months (peer median +3.2%); the operating margin is 8.9% (peer median -0.8%).

Valuation It trades at 34.9× forward earnings against a peer median of 24.7× (2nd most expensive of 7).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -10 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.6 points above its cost of capital (5.0% WACC).

Credit Pharming has 1 bond outstanding ($111M).

Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026PHARM.AS 95Peer median 75
Six months, rebased to 100: Pharming against the median of its 20 peers (local-currency closes).

Pharming financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€333M€333M€275M€227M€196M
Revenue growth—+21%+21%+16%—
Gross profit€276M€283M€232M€193M€175M
EBITDA€40.1M€28.0M€6.82M-€10.2M€12.0M
Net income€20.9M€2.53M-€10.9M-€9.76M€13.0M
Free cash flow€23.7M€43.3M-€6.49M-€20.9M€16.0M
Capital expenditure€751,596€668,983€735,885€1.35M€1.88M
Total debt€101M€98.6M€108M€155M€156M

Quarterly statements and history in the cockpit →

Pharming competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-20%0%+20%006120600771SANOFICONR4521CRVS069620086450688176688621000597AKTS6885533002672595000813603229IMTX002082PHARM.AS6-month return →1-month return →
Up and to the right = strong over both horizons. Pharming is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%10×20×30×40×600771SANOFICONR4521069620086450688621PHARM.ASRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Pharming is the large dot.

Capital: growth delivered against growth the price implies

-40%-20%0%+20%-40%-20%0%20%600771SANOFICONR086450000597688553002082PHARM.ASGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Pharming is the large dot.

Pharming competitors and peer comparison

How Pharming compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Pharming against its 20 peers (data as of 18 Nov 2026)
MeasurePHARM.ASPeer medianRank in peer set
1-month return+30.9%-11.6%highest of 21
6-month return-5.8%-26.0%3rd highest of 19
Distance from 52-week high-38.6%-43.7%8th highest of 21
Revenue growth (TTM)+1.7%+3.2%10th highest of 19
Operating margin8.9%-0.8%5th highest of 19
Forward P/E34.9×24.7×2nd most expensive of 7
Growth the price implies (Req g, 7 yrs)2.4%18.6%3rd least demanding of 7
Growth delivered (Del g)+12.4%+1.7%2nd highest of 7
Hurdle (Req g minus delivered)-10.0 pp+10.2 pp2nd least demanding of 7
ROIC minus cost of capital+6.6 pp-2.9 pp2nd highest of 15
EV / EBITDA18.1×8.8×2nd most expensive of 6
Net debt / EBITDA-1.6×-0.3×2nd least indebted of 6

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Pharming PHARM.ASNetherlands$867M-6%+2%9%34.9×2.4%+12.4%
SK Discovery 006120.KSSouth Korea$866M+25%+24%3%n/an/an/a
GuangYuYuan Chinese Herbal Medicine 600771.SSChina$866M-26%-6%5%38.3×31.7%+4.2%
Sanofi Consumer Healthcare India SANOFICONR.NSIndia$869M-26%+23%36%28.1×17.7%+22.7%
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%21.4×n/an/a
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%9.0×n/an/a
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%14.0×-4.2%+10.6%
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%n/an/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%29.0×n/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%n/a-7.6%-0.7%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%n/an/an/a
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%n/a19.4%-6.0%
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%n/an/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%n/an/an/a
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%n/an/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%n/an/an/a
Immatics IMTXUnited States$913M-46%-44%-589%n/an/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%n/a27.7%-39.5%

Pharming bonds and credit

Pharming has 1 bond outstanding with $111M face value.

Every bond, yield and spread in the cockpit →

Questions

Which companies are Pharming's closest peers?
The cockpit's peer set: SK Discovery (006120.KS), GuangYuYuan Chinese Herbal Medicine (600771.SS), Sanofi Consumer Healthcare India (SANOFICONR.NS), City Therapeutics (CTY), Kaken Pharmaceutical (4521.T), Corvus Pharmaceuticals (CRVS), Daewoong Pharm (069620.KS), DongKook Pharmaceutical (086450.KS).
Is Pharming expensive compared with its peers?
On forward p/e it trades at 34.9× against a peer median of 24.7×, 2nd most expensive of 7 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -10 pp: the price already allows for a slowdown.
How has Pharming stock performed?
Over six months to 18 Nov 2026 the shares returned -5.8% against -26.0% for the median peer; over one year -21.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.